Cell and Gene Therapies in Ophthalmology – Disease Overview, Treatment Options and Future Market Assessment

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Currently, there are eight cell and gene therapies (CGTs) on the market for various ophthalmology indications. These comprise Spark Therapeutics' Luxturna (voretigene neparvovec), which is indicated for retinitis pigmentosa (retinitis) and Leber congenital amaurosis (LCA), is marketed globally, and is the only gene therapy on the market within the ophthalmology space. All other marketed CGTs are cell therapies. Holostem Terapie Avanzate’s Holoclar is indicated for limbal stem cell deficiency (LSCD) and marketed in Europe. Fujifilm’s Nepic, J.Tec’s Ocural, and Hirosaki Lifescience Innovation’s Sakracy are all indicated for LSCD and marketed in Japan. Aurion Biotechnologies' Vyznova is indicated for corneal edema and marketed in Japan. Reliance Life Sciences' ReliNethra is indicated for LSCD and ReliNethra C is indicated for allergic conjunctivitis, blepharoconjunctivitis, and pterygium, and both are marketed in India.

Generally, marketed CGTs target severe and rare diseases for which there are a lack of alternative treatments. The course per therapy is considerably high due to the associated R&D costs and the relatively small patient populations. Pricing and reimbursement could limit the potential sales revenue of CGTs.

Throughout the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and India), CGT guidelines have been published covering: Chemistry, Manufacturing, and Controls (CMC), preclinical assessment, and clinical trials. The FDA provides a guidance specifically for the application of gene therapy for retinal disorders.

CGTs are in development for 38 ophthalmology indications and span almost 500 assets from discovery to pre-registration phases. The top five ophthalmology indications with the most CGT pipeline assets are age-related macular degeneration (AMD), retinitis, glaucoma, LCA, and retinopathy. The pipeline is concentrated towards the stages of drug development, such as investigational new drug (IND)/clinical trial application (CTA) filed, preclinical, and discovery.

GlobalData anticipates that the global CGT market value in the ophthalmology space will experience moderate growth. Sales are expected to increase from $46 million in 2023 to $3.0 billion in 2029, at a compound annual growth rate (CAGR) of 50.8%. Gene therapies are expected to dominate the CGT market in ophthalmology. This is attributed to the high number of gene therapy assets (74.6% of total assets) in the pipeline, and strong players such as Spark Therapeutics, with its marketed product Luxturna.

Scope

Overview of cell and gene therapies (CGT) in ophthalmology. The report focuses on the marketed CGT assets addressing ophthalmology indications as well as the top five ophthalmology indications with the most CGT pipeline assets. Clients will gain insight into the competitive landscape of leading CGT agents in ophthalmology including launch date projections, analyst consensus forecasts, likelihood of approval analysis, and commentary on current and future players. The report also includes outlook from three key opinion leaders in the 5EU, and US, and analyses key challenges and opportunities in the application of CGTs in ophthalmology. Additionally, the report includes commentary on the regulatory landscape of CGTs and on the reimbursement environment.

Key Highlights

Report deliverable includes a PowerPoint report.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

• Develop business strategies by understanding the trends shaping and driving the CGT in ophthalmology market.

• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the opthalmology CGT therapeutics market in the future.

• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Spark Therapeutics
Novartis
Roche
Johnson & Johnson
AbbVie
RegenxBio
Holostem
Fujifilm Holdings Co
Aurion Biotech
Japan Tissue Engineering Co

Table of Contents

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

3. Current Treatment Options

3.1. What is Cell & Gene Therapy?

3.2. Marketed Product Profiles – Gene Therapy

3.3. Marketed Product Profiles – Cell Therapy

3.4. History of the Development of CGT in Ophthalmology

3.5. Commercial Activities of Marketed CGTs in Ophthalmology

3.6. Challenges and Opportunities in CGT in Ophthalmology

4. Pricing and Reimbursement Assessment

4.1. Price of Gene Therapy and Cell Therapy

4.2. Pricing and Reimbursement Case Study: Luxturna

5. Regulations

5.1. Regulation of CGTs in the 8MM

5.2. FDA Guidance for Industry – Human Gene Therapy for Retinal Disorders

6. Future Market Assessment

6.1. Top 20 Ophthalmology Indications with CGT Development

6.2. Top Five Ophthalmology Indications with the Most CGT Pipeline Assets

6.3. Top Five Ophthalmology Indications Stratified by Molecule Type

6.4. Ophthalmology CGT Pipeline Assets

6.5. CGT in Ophthalmology – Phase III and II/III

6.6. Additional Players Expected to Join the Competition Within Five Years

6.7. Industry Trends in the Application of CGTs in Ophthalmology

6.8. CGT Market Catalysts in 2024

7. Likelihood of Approval and Phase – Transition Success Rate Analysis

7.1. CGT Candidates Typically Have Lower Than Average LoA and PTSR

8. Sales Forecast

8.1. Sales are forecast to reach $3.0 billion by 2029

9. Appendix

9.1. Methodology

9.2. Primary Research: Key Opinion Leader Information

9.3. About the Authors

10. Contact Us

Frequently asked questions

Cell and Gene Therapies in Ophthalmology – Disease Overview, Treatment Options and Future Market Assessment standard reports
Currency USD
$6,995

Can be used by individual purchaser only

$20,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Cell and Gene Therapies in Ophthalmology – Disease Overview, Treatment Options and Future Market Assessment was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cell and Gene Therapies in Ophthalmology – Disease Overview, Treatment Options and Future Market Assessment in real time.

  • Access a live Cell and Gene Therapies in Ophthalmology – Disease Overview, Treatment Options and Future Market Assessment dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.